Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction–associated steatotic liver disease.
Authors
Hirokazu Takahashi
Liver Center, Saga University Hospital, Saga, Japan
Hirokazu Takahashi , Yuichi Koshiyama , Yasuhide Mitsumoto , Takashi Kobayashi , Hideki Hayashi , Taeang Arai , Koji Sawada , Michihiro Nonaka , Takashi Nakahara , Kengo Tomita , Takanori Ito , Kazuo Notsumata , Yuya Seko , Hideki Fujii , Shinichi Aishima , Masato Yoneda , Hidenori Toyoda , Yoshio Sumida , Atsushi Nakajima , Takeshi Okanoue
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 493)
DOI
10.1200/JCO.2024.42.3_suppl.493
Abstract #
493
Poster Bd #
C18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.
First Author: David Edward Kaplan
Poster
2022 ASCO Annual Meeting
ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).
First Author: Wen Wee Ma
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The therapeutic strategy for choosing lenvatinib in systemic therapy for unresectable hepatocellular carcinoma.
First Author: Kaoru Tsuchiya
Poster
2020 ASCO Virtual Scientific Program
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
First Author: Arndt Vogel